Baidu
map

Science:细菌新生存策略发现或促药物研发

2013-01-09 Science EurekAlert.org网站

  研究人员发现了当受到抗生素围攻时某些细菌采取的一种新的存活方式。这种存活机制与其它已知的细菌存活策略有着根本的不同。了解这一点可能对设计以难治菌株为标靶的药物有用,例如耐药性结核病——这是一个正在变得越来越紧迫的公共卫生问题。这项研究所基于的是耻垢分枝杆菌,它是一种与TB致病菌有亲缘的细菌。   以往的实验显示,某些细菌在接触抗生素时能够存活是因为在其菌群中存在着一群不进行细胞分裂的“耐药株


  研究人员发现了当受到抗生素围攻时某些细菌采取的一种新的存活方式。这种存活机制与其它已知的细菌存活策略有着根本的不同。了解这一点可能对设计以难治菌株为标靶的药物有用,例如耐药性结核病——这是一个正在变得越来越紧迫的公共卫生问题。这项研究所基于的是耻垢分枝杆菌,它是一种与TB致病菌有亲缘的细菌。

  以往的实验显示,某些细菌在接触抗生素时能够存活是因为在其菌群中存在着一群不进行细胞分裂的“耐药株细胞”,它们甚至是在抗生素治疗开始之前就已经存在于菌群之中了。 Wakamoto及其同事现在报告说,不进行细胞分裂的耐药株细胞与接触异烟肼的耻垢分枝杆菌的存活无关。实际上,细胞的存活与其生长率毫无关系。相反,一种叫做KatG的细菌酶的随机脉冲使得某些细菌细胞在抗生素治疗中存活下来成为可能。

  研究人员对经过异烟肼处理的微流控培养中的单一的耻垢分枝杆菌细胞进行了研究。该药是一种“前体药物”,它要在给药后并与细胞中某些化合物相互作用之后才会变得有活性。在耻垢分枝杆菌的这种情况下,是KatG激活了异烟肼。个体细菌细胞的命运不与其生长速度相关,但与其KatG的产出相关。每个细菌细胞以随机脉冲方式所产生的KatG决定了该细菌细胞存活的机会。研究人员得出结论:在某些细胞中,在有些脉冲间期中,前体药物的酶转化几乎是不可能的。因此,有一些细菌细胞可能会避免被激活的抗生素杀灭。


ABSTRACT
Exposure of an isogenic bacterial population to a cidal antibiotic typically fails to eliminate a small fraction of refractory cells. Historically, fractional killing has been attributed to infrequently dividing or nondividing “persisters.” Using microfluidic cultures and time-lapse microscopy, we found that Mycobacterium smegmatis persists by dividing in the presence of the drug isoniazid (INH). Although persistence in these studies was characterized by stable numbers of cells, this apparent stability was actually a dynamic state of balanced division and death. Single cells expressed catalase-peroxidase (KatG), which activates INH, in stochastic pulses that were negatively correlated with cell survival. These behaviors may reflect epigenetic effects, because KatG pulsing and death were correlated between sibling cells. Selection of lineages characterized by infrequent KatG pulsing could allow nonresponsive adaptation during prolonged drug exposure.

    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1299732, encodeId=08b01299e3281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301398, encodeId=e6181301398ef, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374685, encodeId=259113e46853a, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=)]
    2013-01-11 lqvr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1299732, encodeId=08b01299e3281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301398, encodeId=e6181301398ef, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374685, encodeId=259113e46853a, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1299732, encodeId=08b01299e3281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301398, encodeId=e6181301398ef, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374685, encodeId=259113e46853a, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Fri Jan 11 05:11:00 CST 2013, time=2013-01-11, status=1, ipAttribution=)]
    2013-01-11 jichang
Baidu
map
Baidu
map
Baidu
map